Loading...

ニュース

Insomnia and schizophrenia innovative treatments approved

2020-02-03


Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide secreted by the hypothalamus and plays an important role in maintaining arousal. By blocking the interaction of orexin A and orexin B with orexin receptor 1 (OXR1) and orexin receptor 2 (OXR2), Dayvigo can inhibit arousal and thus treat various symptoms of insomnia. Because Dayvigo's brain region is more specific than other drugs for insomnia, it has fewer side effects.


The approval is based on the results of two key Phase 3 studies (SUNRISE 2 and SUNRISE 1) that evaluated Dayvigo's efficacy in a total of approximately 2,000 adult patients with insomnia compared to the control group and placebo. The results of these studies indicate that Dayvigo shows a statistically significant advantage in both subjective and objective evaluations in terms of falling asleep and sleep maintenance compared to placebo.


当社は、このウェブサイトの利用状況をより良く理解し、今後のウェブサイト訪問時の体験を向上させるために、クッキーを使用したいと考えています。この設定は、ブラウザの設定で変更できます。クッキーの使用に関する詳細については、当社の プライバシー ポリシー を参照してください。